Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors

Future Oncology
Shanthi KanthalaSeetharama Jois

Abstract

Expression of the EGF receptors (EGFRs) is abnormally high in many types of cancer, including 25% of lung cancers. Successful treatments target mutations in the EGFR tyrosine kinase domain with EGFR tyrosine kinase inhibitors (TKIs). However, almost all patients develop resistance to this treatment, and acquired resistance to first-generation TKI has prompted the clinical development of a second generation of EGFR TKI. Because of the development of resistance to treatment of TKIs, there is a need to collect genomic information about EGFR levels in non-small-cell lung cancer patients. Herein, we focus on current molecular targets that have therapies available as well as other targets for which therapies will be available in the near future.

References

Apr 25, 2000·Cancer Control : Journal of the Moffitt Cancer Center·W M Alberts
Apr 2, 2004·Pharmacology & Therapeutics·Jennifer Rubin Grandis, John C Sok
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 16, 2006·The New England Journal of Medicine·Federico CappuzzoMarileila Varella-Garcia
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Jul 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fred R HirschDavid R Gandara
Aug 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jenn-Yu WuPan-Chyr Yang
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alain C MitaAnthony W Tolcher
Apr 16, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Glenn LiuBradley Somer
Jul 7, 2009·Journal of Experimental & Clinical Cancer Research : CR·Zuleyha CalikusuOzgur Ozyilkan
Aug 6, 2009·Expert Opinion on Biological Therapy·Malcolm R AlisonShahriar Islam
May 19, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistJean-Charles Soria
Jul 27, 2010·Journal of Molecular Biology·Robert D FisherCharles Eigenbrot
Sep 8, 2010·Seminars in Cell & Developmental Biology·Dhara N AminMark M Moasser
Oct 6, 2010·Journal of Biomolecular Structure & Dynamics·Sashikanth BanappagariSeetharama D Satyanarayanajois
Oct 28, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Joan H SchillerMark A Socinski
Nov 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corey J LangerJean-Charles Soria
Dec 2, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Giorgio ScagliottiChandra P Belani
Jan 21, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yelena Y JanjigianGregory J Riely
Jun 18, 2011·Expert Opinion on Biological Therapy·Rodrigo Dienstmann, Enriqueta Felip
Jul 1, 2011·The New England Journal of Medicine·UNKNOWN National Lung Screening Trial Research TeamJoRean D Sicks
Jul 6, 2011·Seminars in Roentgenology·Aoife McErlean, Michelle S Ginsberg
Jul 7, 2011·International Journal of Cancer. Journal International Du Cancer·Mi Young ChaMaeng Sup Kim
Sep 16, 2011·International Journal of Cancer. Journal International Du Cancer·Hongzheng ZhangDong M Shin
Nov 8, 2011·Clinics in Chest Medicine·Charles S Dela CruzRichard A Matthay
Jan 24, 2012·The European Respiratory Journal·Chiara ScocciantiUNKNOWN European Early Lung Cancer Consortium
Feb 14, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J De GrèveD Schallier
May 2, 2012·Molecular Biology Reports·Sicong ZengGuangxiu Lu
Jun 27, 2012·Journal of Biomolecular Structure & Dynamics·Sashikanth BanappagariSeetharama Satyanarayanajois
Jul 5, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria E ArcilaMarc Ladanyi
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S PetersUNKNOWN ESMO Guidelines Working Group
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tianhong LiDavid R Gandara
Mar 14, 2013·International Journal of Molecular Medicine·Haizhong YuYi Qin

❮ Previous
Next ❯

Citations

May 10, 2017·The International Journal of Biological Markers·Young San KoJung-Soo Pyo
Mar 15, 2019·Anti-cancer Agents in Medicinal Chemistry·Shui-Ming BaoWen-Dai Bao
Dec 17, 2020·Biomolecules·Eline SoetensXavier Saelens
Mar 12, 2019·Current Medicinal Chemistry·Sitanshu S SinghSeetharama D Jois
Mar 20, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Sheng Tan, Guoxiang Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.